International Assets Investment Management LLC Acquires New Position in Catalent, Inc. (NYSE:CTLT)

International Assets Investment Management LLC acquired a new stake in Catalent, Inc. (NYSE:CTLT) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,962 shares of the company’s stock, valued at approximately $6,720,000.

A number of other hedge funds have also recently modified their holdings of CTLT. Cadian Capital Management LP grew its holdings in shares of Catalent by 91.0% in the third quarter. Cadian Capital Management LP now owns 5,304,784 shares of the company’s stock valued at $241,527,000 after purchasing an additional 2,526,750 shares during the period. Barclays PLC grew its holdings in shares of Catalent by 41.7% in the third quarter. Barclays PLC now owns 4,797,718 shares of the company’s stock valued at $218,440,000 after purchasing an additional 1,412,058 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Catalent by 65.9% in the third quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company’s stock valued at $158,601,000 after purchasing an additional 1,384,313 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Catalent by 50.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,536,313 shares of the company’s stock valued at $69,948,000 after purchasing an additional 516,464 shares during the period. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Catalent by 29.6% in the third quarter. Assenagon Asset Management S.A. now owns 1,875,829 shares of the company’s stock valued at $85,406,000 after purchasing an additional 428,260 shares during the period.

Analyst Ratings Changes

CTLT has been the topic of a number of recent analyst reports. UBS Group reaffirmed a “neutral” rating and issued a $63.50 target price (up previously from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research report on Tuesday, February 20th. StockNews.com started coverage on shares of Catalent in a research report on Sunday. They issued a “sell” rating on the stock. Stephens reissued an “equal weight” rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, April 4th. Finally, Barclays increased their price target on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Catalent presently has a consensus rating of “Hold” and an average price target of $52.46.

Catalent Stock Up 0.3 %

Shares of NYSE:CTLT opened at $56.53 on Wednesday. The firm’s 50 day moving average price is $56.40 and its 200 day moving average price is $49.26. The stock has a market cap of $10.23 billion, a price-to-earnings ratio of -8.31, a price-to-earnings-growth ratio of 6.09 and a beta of 1.18. Catalent, Inc. has a fifty-two week low of $31.45 and a fifty-two week high of $60.20. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34.

Catalent (NYSE:CTLT) last issued its earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The firm’s revenue was down 10.2% compared to the same quarter last year. During the same period last year, the business earned $0.62 EPS. As a group, equities research analysts predict that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.